In the News

Article

Break it Down: Recce partners with the US Army

Published 28 Apr 2025

Article

Recce to expand Phase II trial for diabetic foot infections

Published 22 Apr 2025

Article

Recce raising up to $15.8m for Phase III trials

Published 10 Apr 2025

Article

Biocurious: For Recce, our near neighbour was the obvious place to launch a diabetes-related trial

Published 03 Apr 2025

Article

Synthetic Gel Shows Utility Across ABSSSI, Company Sees Other Indications

Published 06 Mar 2025

Article

Australian biotech points to potential superbug use as gel treats skin infections in phase 2 trial

Published 20 Feb 2025

Article

Recce soars on phase II skin infection trial results

Published 17 Feb 2025

Article

Recce Pharmaceuticals doses all patients in phase II skin infection trial

Published 29 Jan 2025

Article

Recce Pharmaceuticals doses all patients in Phase 2 clinical trial of RECCE® 327 topical gel for skin infections

Published 21 Jan 2025

Article

Recce gets Indonesian nod for phase III trial of diabetic foot infection treatment

Published 09 Dec 2024

Article

Complete patent protection for 2 Recce anti-infective treatments

Published 26 Nov 2024

Article

Recce green lit to begin dosing in registrational Phase 3 trial for diabetic foot infections

Published 11 Nov 2024

Article

From No More Tears to no more superbug fears

Published 21 Oct 2024

Article

Here’s why you’ll see more ASX biotechs focus on Asia in the years ahead!

Published 16 Oct 2024

Article

Local Pharma Fights Superbugs

Published 14 Oct 2024

Article

Recce’s Phase 2 trial for skin infections hits midway recruitment milestone

Published 09 Oct 2024

Article

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Published 02 Oct 2024

Article

Recce Pharmaceuticals Advances Antibiotic Development to Combat Antimicrobial Resistance

Published 09 Sep 2024

Article

Recce’s reconnaissance against superbug – infiltrate, eliminate, escape undetected

Published 09 Sep 2024

Article

Recce Pharmaceuticals Delivers the Opening Address at World Antimicrobial Resistance Congress 2024

Published 06 Sep 2024

Article

Recce Pharmaceuticals – Executive Interview

Published 07 Aug 2024

Article

Recce Pharmaceuticals more than doubles SPP target with A$4.4 million taking raise proceeds to A$12.4 million

Published 05 Aug 2024

Article

Recce scores US$2M deal from US Department of Defense for burn wound infections gel

Published 16 Jul 2024

Article

Recce Pharmaceuticals granted US$2 million from US Department of Defense for RECCE® 327 Gel

Published 15 Jul 2024

Article

Recce Pharmaceuticals reports positive data from Phase 1/2 UTI/urosepsis rapid infusion clinical trial of RECCE® 327

Published 28 Jun 2024

Article

Recce Starts Phase 2 R327 Gel trial for bacterial skin infections

Published 25 Jun 2024

Article

Recce Pharmaceuticals lands WHO Antibacterial Products in Clinical Development listing for RECCE® 327

Published 18 Jun 2024

Article

Recce completes cohort dosing for Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial with fastest infusion times yet; key safety review inbound

Published 12 Jun 2024

Article

Recce wraps up IV UTI trial with fastest infusion times yet; key safety review inbound

Published 11 Jun 2024

Article

Webinar: What investors should know about what it takes for ASX-listed companies to get medical developments to market

Published 27 May 2024

Article

Recce Pharma heading closer to full efficacy data for flagship R327

Published 15 May 2024

Article

Recce Pharmaceuticals makes breakthrough in lung infection treatment with nebulised RECCE® 327

Published 09 May 2024

Article

Recce Pharma picks up Chinese patent for anti-infective drugs

Published 07 May 2024

Article

Recce weighs in on Q1 2024 as cash increases 100%

Published 22 Apr 2024

Article

Recce Pharmaceuticals up 6% on new antibiotic production milestone

Published 16 Apr 2024

Article

Recce Pharmaceuticals selected to participate in UK Government Innovation Agency’s AMR Mission 2024

Published 11 Apr 2024

Article

Recce gearing up for Indonesian trials; US DOD looking at R327 burn gel

Published 09 Apr 2024

Article

Recce gearing up for Indonesian trials; US DOD looking at R327 burn gel

Published 08 Apr 2024

Article

Recce Pharmaceuticals inks new patent for flagship drug in Israel

Published 03 Apr 2024

Article

Recce reaches testing milestone for UTI, Uroseptis antibiotic

Published 22 Mar 2024

Article

Recce Pharmaceuticals hits major milestone in R327 clinical trial for UTI/urosepsis

Published 18 Mar 2024

Article

Recce reaches testing milestone for UTI, Urosepsis antibiotic

Published 17 Mar 2024

Article

Recce Pharma (ASX:RCE) kicks-off dosing for next cohort of UTI trial

Published 13 Mar 2024

Article

Recce Pharmaceuticals secures AUD$11.18M from Endpoints Capital

Published 13 Mar 2024

Article

Biotech around the World: The Low-Down on the Land Down Under

Published 03 Mar 2024

Article

BioBoss Podcast - CEO James Graham

Published 29 Feb 2024

Article

Recce Pharmaceuticals leads the way in collaborative Anti-Infective research

Published 27 Feb 2024

Article

Recce Pharmaceuticals wins safety approval to expand wound infection trial

Published 26 Feb 2024

Article

Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances

Published 15 Feb 2024

Article

Recce Pharmaceuticals Establishes Strategic Partnership in South-East Asia to Accelerate Clinical Program

Published 08 Feb 2024

Article

Recce Pharmaceuticals teams with leading Indonesian biomed company for anti-infective push

Published 06 Feb 2024

Article

Recce Pharmaceuticals to expand diabetes foot infection trial as results prove strong

Published 28 Jan 2024

Article

Recce Pharmaceuticals to expand diabetes foot infection trial as results prove strong

Published 18 Jan 2024

Article

Revolutionary Antibiotic-Resistant Gonorrhea Treatment: A Possible Breakthrough with Recce 327

Published 11 Jan 2024

Article

4 Biotech Executives Share Strategies Behind Successful Fund Raises

Published 08 Jan 2024

Article

Recce Pharmaceuticals higher on positive efficacy data in Murdoch Children’s Research Institute UTI study

Published 08 Jan 2024

Article

Recce Pharmaceuticals — Landmark commitment helps fund R&D costs

Published 22 Dec 2023

Article

Recce secures Australia’s largest-ever $11m Advanced Overseas R&D Finding

Published 20 Dec 2023

Article

Recce Pharmaceuticals awarded A$11 million Advanced Overseas Finding for anti-viral R&D costs

Published 17 Dec 2023

Article

Recce Pharmaceuticals awarded $43.7 million Advanced Overseas Finding for synthetic anti-infective development program

Published 15 Dec 2023

Article

Recce Pharmaceuticals lead anti-infective R327 shows promise against deadly STD in latest animal study

Published 14 Dec 2023

Article

Antimicrobial resistance with Recce Pharmaceuticals

Published 06 Dec 2023

Article

Engineering the future of antibiotics

Published 06 Dec 2023

Article

Recce Pharmaceuticals wins Canadian patent for flagship anti-infectives

Published 23 Nov 2023

Article

Recce Pharmaceuticals doses first patients over 15 minutes in R327 UTI/urosepsis trial

Published 07 Nov 2023

Article

Recce Pharmaceuticals completes dosing of first subjects at faster infusion rate in RECCE® 327 clinical trial

Published 07 Nov 2023

Article

Recce Pharmaceuticals presents at Ord Minnett Healthcare Forum

Published 01 Nov 2023

Article

Recce Pharma welcomes approval for faster RECCE327 infusion rate

Published 25 Oct 2023

Article

Recce Pharmaceuticals accelerates R327 trial for UTI patients with faster infusion rate approval

Published 24 Oct 2023

Article

Busiest quarter for Recce Pharmaceuticals: Cashed up for next phases of drug development

Published 23 Oct 2023

Article

Recce Pharma says commercial potential of its anti-infectives is gaining recognition

Published 11 Oct 2023

Article

Recce Pharmaceuticals raise to progress advanced anti-infective

Published 09 Oct 2023

Article

Global fund takes stake in Recce as synthetic antibiotic developer raises $11m

Published 06 Oct 2023

Article

Recce Pharmaceuticals raises further funds to progress trials from entitlement shortfall

Published 06 Oct 2023

Article

Recce Pharmaceuticals advances anti-infective development and clinical trials in FY23

Published 02 Oct 2023

Article

Recce Pharmaceuticals (ASX:RCE) completes cohort dosing in UTI rapid infusion trial

Published 22 Sep 2023

Article

Recce Pharmaceuticals (ASX:RCE) paves its way to commercialisation with breakthrough antibiotic, R327

Published 20 Sep 2023

Article

Recce Pharmaceuticals (ASX:RCE) receives green light for higher dose in rapid infusion phase I/II UTI trial

Published 28 Aug 2023

Article

Recce Pharmaceuticals — R327 progressing in rapid infusion study

Published 24 Aug 2023

Article

Recce Pharmaceuticals (ASX:RCE) doses phase I/II patients in R327 diabetic foot infection trial

Published 22 Aug 2023

Article

Recce Pharmaceuticals (ASX:RCE) concludes stage one analysis of phase I/II R327 topical trial for burn wounds

Published 21 Aug 2023

Article

Recce Pharmaceuticals’ (ASX:RCE) new R327G shows positive response in treatment of antibiotic-resistant infections

Published 08 Aug 2023

Article

Recce Pharmaceuticals awarded Australian patent for lead anti-infectives

Published 04 Aug 2023

Article

Recce Pharmaceuticals (ASX:RCE) charges on with phase I/II UTI trial ahead of schedule

Published 24 Jul 2023

Article

Recce Pharmaceuticals (ASX:RCE) reports “positive” results from phase one R327 clinical trial

Published 19 Jul 2023

Article

Recce Pharmaceuticals verifies positive Phase 1 data from R327 intravenous study

Published 19 Jul 2023

Article

Recce Pharmaceuticals receives A$801,604 in R&D rebate advance

Published 12 Jul 2023

Article

Recce Pharmaceuticals — Gearing up for more R327 studies

Published 11 Jul 2023

Article

Recce Pharmaceuticals (ASX:RCE) kicks off phase I/II UTI trial

Published 10 Jul 2023

Article

Recce Pharmaceuticals lands ethics approval for expanded UTI studies

Published 30 Jun 2023

Article

Recce Pharmaceuticals receives Ethics Approval to expand R327 Faster Infusion, Phase I/II Clinical Trial

Published 29 Jun 2023

Article

Recce Pharmaceuticals (ASX:RCE) gains ethics approval to expand phase I/II trial of R327

Published 29 Jun 2023

Article

Recce Pharmaceuticals recruits outpatient nurses to drive “largest in Australia” diabetic foot infection clinical trial

Published 29 May 2023

Article

Recce Pharmaceuticals (ASX:RCE) appoints outpatient nurses from Ascott

Published 29 May 2023

Article

Recce Pharmaceuticals (ASX:RCE) secures sponsorship to attend BIO Korea 2023

Published 08 May 2023

Article

Recce Pharmaceuticals (ASX:RCE) receives ‘intent to grant’ Patent Family 4 for anti-infectives

Published 11 Apr 2023

Article

Recce Pharmaceuticals (ASX:RCE) selects CMAX for phase I/II UTI clinical trial

Published 20 Feb 2023

Article

Recce Pharmaceuticals boosts finances with A$6.21 million in R&D rebate payments

Published 25 Jan 2023

Article

For this pharma boss, fishing is an experience in positivity

Published 16 Jan 2023

Article

Recce Pharmaceuticals (ASX:RCE) granted notification of intent for Australian patent

Published 10 Jan 2023

Article

ASX:RCE

Published 12 Apr 2023

Recce Pharmaceuticals Ltd attracts $1.8 million as it moves toward human clinical trials Recce Pharmaceuticals Ltd (ASX:RCE) has raised about $1.8 million from sophisticated and institutional investors...

Article

Recce Pharmaceuticals locks

Published 12 Apr 2023

In US patent for synthetic antibiotic to target growing superbug problem Recce Pharmaceuticals (ASX: RCE) has locked-in a US patent for its broad-spectrum synthetic antibiotics, paving the way for the...

Article

Director Trades

Published 12 Apr 2023

A millennial director put his $100k into his own company rather than a house deposit It was millionaire’s row last week in small cap land, with four multi-million dollar trades and one that was pretty close...

Article

Health & Biotech

Published 12 Apr 2023

The biotech veteran chasing a billion-dollar pot of gold He was famously worth over $130 million — on paper at least — when he was running Chemeq, which blew itsel up a decade ago after he left.

Article

Health & Biotech

Published 12 Apr 2023

Why this 29-year-old investor took a six-figure stake in a $17m biotech company I prefer to have my money be working for me,” he tells Stockhead. “I don’t want it to be at the beck and call of Trump having...

Article

Sky Business News

Published 12 Apr 2023

Interview with Peter Switzer One of the worrying trends in hospitals are superbugs, raising question marks over the efficacy of antibiotics. Listed company Recce target is targeting this issue ..

Article

S&P Global

Published 12 Apr 2023

Small companies play big role in search for superbug killers Superbugs are quickly becoming a top health concern, yet there has been a roughly 30-year dry spell in antibiotic molecule discovery...

Article

The West Australian

Published 12 Apr 2023

WA tests synthetic antibiotic A Perth-based pharmaceutical research company is a step closer to developing a new class of synthetic antibiotics to overcome superbugs. Recce Limited has started ...

Article

The Australian

Published 12 Apr 2023

Australia’s Recce strives for immune-proof super-antibiotic Introductory offers to be billed as follows: The Australian Digital Subscription costs 50c per day, billed monthly (min cost up...

Article

BioWorld

Published 12 Apr 2023

Recce nears clinic with ‘master key’ antibiotic to take on superbugs PERTH, Australia – A new class of synthetic antibiotics with broad-spectrum activity is being developed by Sydney-based...

Article

Fighting Antibiotic Resistance

Published 12 Apr 2023

The world needs new classes of antibiotics Antibiotics The world needs new classes of antibiotics Antibiotics are used as our frontline treatment...

Article

Nature Biopharma

Published 12 Apr 2023

New class of synthetic antibiotics set to tackle superbugs PERTH, Australia – A new class of synthetic antibiotics with broad-spectrum activity is being developed by Sydney-based...

Article

Coronavirus crisis

Published 12 Apr 2023

Recce Pharmaceuticals is among dozens of WA-founded biotech companies that are making serious waves in the medical research sector, with COVID-19 the latest disease in its sights...

Article

The Australian - Research Special Report 2020

Published 12 Apr 2023

A revolutionary approach to medicine: synthetic anti-Infectives Anti-infectives are used as our frontline treatment for everyday and life threatening bacteria and viral infections…

Article

Pharmafiles 2020: Synthetic Anti-Infectives

Published 12 Apr 2023

AMR is a ticking time bomb argues Recce CEO James Graham...

Article

H.C. Wainwright Global Life Sciences Conference

Published 12 Apr 2023

Click here for full Press Release and Presentation

Article

AusBiotech Journal 2020 Vol 30

Published 12 Apr 2023

A NEW CLASS OF ANTIBIOTICS

Article

AusBiotech Journal 2020 Vol 30

Published 12 Apr 2023

ADVANCING THE ‘ARMS RACE’ against antibiotic-resistant superbugs

Article

PharmaShots Interview w Recce CEO James Graham

Published 12 Apr 2023

James Graham, CEO of Recce Pharmaceuticals shared his views on the multiple patient dosing in P-I/II clinical trial of RECCE 327 (R327) for the treatment of infected burn wounds.

Article

AusBiotech Journal 2021 Vol 31

Published 12 Apr 2023

A REVOLUTIONARY APPROACH against antimicrobial resistance

Article

Recce tapping European investor interest

Published 12 Apr 2023

Recce listed on the Frankfurt Stock Exchange and is working with German asset manager DGWA as it embarks on a global superbug-fighting strategy.

Article

Recce tapping European investor interest

Published 12 Apr 2023

Recce listed on the Frankfurt Stock Exchange and is working with German asset manager DGWA as it embarks on a global superbug-fighting strategy.

Article

Proactive Investors - The smart money in medicine: the silent pandemic

Published 12 Apr 2023

Recce Pharmaceuticals is working on a solution.